# Vinay Prasad

Type: Person

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/vinay-prasad
Canonical HTML page: https://getfinancebrief.com/entity/vinay-prasad

## Timeline

- **2026-03-15**: Industry Warning — Editorials warn that erratic FDA behavior is a threat to biotech innovation.
- **2026-02-03**: Refusal to File — FDA regulator Vinay Prasad refuses to review Moderna's flu vaccine application.
- **2025-08-15**: Regulatory Alignment — FDA officials reportedly signal support for Moderna's trial data workaround.
- **2025-01-01**: Grant Rescission — The federal government rescinds hundreds of millions in mRNA research funding.
- **2021-08-01**: Peak Valuation — Moderna reaches a market capitalization of $200 billion during the pandemic height.

## Recent coverage (1 stories)

### FDA Regulatory Shift Threatens Biotech Innovation and Moderna's Recovery
2026-03-16 00:17:19 · Sentiment: Bearish · Impact: 8/10 · Sources: 2

Moderna Inc. faces a critical juncture as the FDA's increasingly erratic regulatory stance and shifting White House sentiment jeopardize the future of mRNA technology. A rare refusal to review the company's flu vaccine data highlights a growing rift between the agency and the industry it oversees, threatening the predictability required for biotech investment.
Full story: https://getfinancebrief.com/story/fda-regulatory-shift-moderna-innovation-threat

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.